康提利桑特+图巴斯丁A杂交物:多功能性醇衍生物作为新的基于HDAC抑制剂的多目标小分子,在神经退行性疾病中具有In Vitro和In Vivo活动
Mireia Toledano-Pinedo1, Alicia Porro-Pérez1, Linda Schäker-Hübner2
1Institute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
Journal of medicinal chemistry
|September 10, 2024
概括
结合Contilisant和Tubastatin A的新混合分子显示出作为强大的HDAC6抑制剂的希望. 这些化合物通过减少关键的病理特征,有效地改善了帕金森病和阿尔茨海默病的模型.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 海斯脱乙酶6 (HDAC6) 是神经退行性疾病的验证标.
- 康提利桑和图巴斯A是已知的具有明显生物活性的药.
- 开发多功能连接体提供了一种解决帕金森病 (PD) 和阿尔茨海默病 (AD) 等复杂病理问题的策略.
研究的目的:
- 设计,合成和评估包含康提利桑特和图巴斯A的药用元素的新型混合配体.
- 为了确定HDAC6.6的强效抑制剂.
- 在PD和AD的临床前模型中评估化合物的治疗潜力.
主要方法:
- 合成15种多功能性醇衍生物作为康提利桑特+图巴斯A杂交物.
- 在体外酶分析以确定HDAC6抑制活性 (IC50值).
- 在Drosophila和Caenorhabditis elegans的PD和AD模型中的体内评估,分别评估表型改善.
主要成果:
- 化合物3和4已成为高强度的HDAC6抑制剂,其IC50值处于纳米分子范围.
- 在PD模型中,化合物3和4减弱了运动缺陷,氧化应激和线粒体功能障碍.
- 在AD模型中,化合物3和4没有表现出毒性,抑制了与年龄有关的,并改善了认知功能.
结论:
- 化合物3和4是具有显著治疗潜力的新型,无毒的多功能连接体.
- 这些混合物有效地针对帕金森病和阿尔茨海默病的关键病理特征.
- 制药剂相对应的开发策略为创建神经退行性疾病的先进治疗方法提供了可行的途径.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
siRNA - Small Interfering RNAs
16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


